Article
Pharmacology & Pharmacy
Ahmed Nader, Elizabeth Alexander, Dimitra Brintziki, Amina Z. Haggag, Stephen A. Harrison, Ian A. Hawes, Marjan Hezareh, Andrew M. Lippa, Arisa Okamasa, Malek Okour, Nobuhiko Okuda, Jennifer E. Sager, Scott Segal, Yuri Shida, Andrew Skingsley, Robert Williams, Esther Y. Yoon, Daren Austin
Summary: This study investigated the pharmacokinetics, safety, and tolerability of Sotrovimab in Japanese and Caucasian participants. The results showed that there were similar exposures of Sotrovimab between Japanese and Caucasian participants, with higher exposures observed in Japanese participants after intramuscular administration. This study suggests that Sotrovimab is safe and effective for the treatment of SARS-CoV-2 infection.
CLINICAL PHARMACOKINETICS
(2023)
Article
Respiratory System
Satoru Inoue, Soniya Vaidya, Hanns-Christian Tillmann, Yohei Sakita, Surendra Machineni, Olivier Heudi, Kenichi Furihata
Summary: The pharmacokinetics of IND, GLY, and MF when delivered as a fixed-dose combination were similar between Japanese and Caucasian male subjects. The IND/GLY/MF combination was safe and well tolerated in both ethnic groups.
BMC PULMONARY MEDICINE
(2021)
Article
Clinical Neurology
Masahiro Takeshima, Kazuhisa Yoshizawa, Minori Enomoto, Masaya Ogasawara, Mizuki Kudo, Yu Itoh, Naoko Ayabe, Yoshikazu Takaesu, Kazuo Mishima
Summary: This study aimed to examine the effect of Japanese policies and novel hypnotics on long-term prescriptions of hypnotics. The results showed that Japanese policies had no statistically significant effect on long-term prescriptions of hypnotics. However, initiating orexin receptor antagonists may be a potential strategy to prevent long-term prescriptions of hypnotics.
PSYCHIATRY AND CLINICAL NEUROSCIENCES
(2023)
Article
Pharmacology & Pharmacy
Narihisa Miyachi, Oleh Zagrijtschuk, Lisa Kang, Katsuya Yonezu, Albert Qin
Summary: The exposure of Ropeginterferon alfa-2b was higher in Japanese subjects compared to Caucasian subjects, with the increase in exposure being greater than dose proportion within the 100-300 μg dose range. Ropeginterferon alfa-2b up to 300 μg was found to be safe and well tolerated.
CLINICAL DRUG INVESTIGATION
(2021)
Article
Pharmacology & Pharmacy
Madhav Sachar, Cheol Hee Park, Luana Pesco-Koplowitz, Barry Koplowitz, Arlo McGinn
Summary: The study evaluated potential pharmacokinetic differences between Caucasian, Japanese, and Chinese populations in terms of Rivoceranib metabolism and pharmacokinetic parameters, with results showing no significant differences that would require dose adjustment.
FUNDAMENTAL & CLINICAL PHARMACOLOGY
(2021)
Article
Pharmacology & Pharmacy
Paulo Teixeira-da-Silva, Jonas Samuel Perez-Blanco, Dolores Santos-Buelga, Maria Jose Otero, Maria Jose Garcia
Summary: The study aimed to explore the pharmacokinetic characteristics of valproic acid (VPA) in a large Caucasian population and establish a robust population pharmacokinetic (PopPK) model. A one-compartment model with first-order absorption and elimination successfully described the data, incorporating factors such as total body weight, age, and comedication with other drugs. Internal and external evaluations showed good predictability of the model, indicating its potential application in precision dosing approaches for clinical patient care.
Article
Psychology, Multidisciplinary
Yuiko Sakuta
Summary: Recent studies have shown that humans can make instantaneous and automatic social evaluations based on facial appearances. This study investigated the universality or cultural differences in impression formation among Japanese children and adults using computer-generated Caucasian faces. The results indicated that impression formation is influenced by age and culture, and different judgment criteria are used for different dimensions of traits in children and adults.
FRONTIERS IN PSYCHOLOGY
(2022)
Article
Clinical Neurology
Priska Kaufmann, Marion Ort, Georg Golor, Ruediger Kornberger, Jasper Dingemanse
Summary: Selective orexin-1 receptor antagonists like ACT-539313 show activity on the CNS and a potential decrease in anxiety/panic symptoms. Clinical studies demonstrate good safety and tolerability of multiple doses of ACT-539313, supporting further investigations into its pharmacological properties.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2021)
Article
Pharmacology & Pharmacy
Ying Jin, Mengyu Zhang, Xiangjie Di, Xiaohui Qi, Li Zheng, Zhenlei Wang
Summary: This study compares the pharmacokinetics of intravenous ibuprofen between Caucasian and Chinese populations using PBPK modeling and simulation. The findings show that the pharmacokinetic profile and parameters of intravenous ibuprofen are similar in both populations, indicating that the dosing scheme can remain the same in Chinese children as in the original regimen.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
(2023)
Article
Pharmacology & Pharmacy
Jiayu Li, Pei Hu, Li Zhou, Fumiko Nagahama, Rui Chen
Summary: This study found ethnic differences in the pharmacokinetics of granisetron patches between Chinese and Caucasian populations, but analysis of a population pharmacokinetic model showed no significant differences in pharmacokinetic parameters between the two groups. Therefore, this study provides valuable insights for optimizing dosage across Chinese and Caucasian populations.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Microbiology
Akira Kawashima, Hieu Tran Trung, Koji Watanabe, Misao Takano, Yoshimi Deguchi, Mai Kinoshita, Haruka Uemura, Yasuaki Yanagawa, Hiroyuki Gatanaga, Yoshimi Kikuchi, Shinichi Oka, Kiyoto Tsuchiya
Summary: Bictegravir (BIC) is a potent integrase strand transfer inhibitor widely used in the treatment of HIV-1. Although its potency and safety have been demonstrated in older patients, PK data remain limited in this patient population. This study collected BIC PK data from 10 older HIV-1-infected patients and showed that PK of BIC are not affected by age, supporting the safe use of this treatment regimen among older patients with HIV-1.
MICROBIOLOGY SPECTRUM
(2023)
Article
Psychiatry
Yoshikazu Takaesu, Hitoshi Sakurai, Yumi Aoki, Masahiro Takeshima, Kenya Ie, Kentaro Matsui, Tomohiro Utsumi, Akiyoshi Shimura, Isa Okajima, Nozomu Kotorii, Hidehisa Yamashita, Masahiro Suzuki, Kenichi Kuriyama, Eiji Shimizu, Kazuo Mishima, Koichiro Watanabe, Ken Inada
Summary: This study investigated the answers to clinical questions about treating insomnia disorder, finding that the use of hypnotic and non-pharmacological treatments varies depending on clinical situations, and alternative treatments can help reduce or stop benzodiazepine hypnotics. Expert consensus suggests that orexin receptor antagonists and sleep hygiene education are recommended as first-line treatments in most clinical situations.
FRONTIERS IN PSYCHIATRY
(2023)
Article
Oncology
Shigehisa Kitano, Yutaka Fujiwara, Toshio Shimizu, Satoru Iwasa, Kan Yonemori, Shunsuke Kondo, Akihiko Shimomura, Takafumi Koyama, Takahiro Ebata, Hiroki Ikezawa, Nozomi Hayata, Yukinori Minoshima, Takuma Miura, Tomoki Kubota, Noboru Yamamoto
Summary: This study investigates the tolerability and safety of lenvatinib plus pembrolizumab in Japanese patients with metastatic solid tumors. The combination therapy showed favorable antitumor activity and no new safety signals were identified. The results support the use of this treatment in Japanese patients.
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2022)
Article
Clinical Neurology
Duanduan Cong, Jie Song, Yue Liu, Yan Tan, Wei Xue, Xiaohui Liu, Wenyuan Qi, Jun Lu, Xiaojuan Yuan, Yongchun Zhou, Ai-Min Hui, Kexin Li
Summary: This study evaluated the PK and PD of OPC in healthy Chinese and Caucasian subjects, showing no significant impact of ethnicity on these parameters. OPC was found to be safe and tolerable in healthy Chinese subjects.
NEUROLOGY AND THERAPY
(2022)
Article
Pharmacology & Pharmacy
Massimo Cella, Jorg Taubel, Irisz Delestre-Levai, Anne Tulard, Andrea Vele, George Georges
Summary: The study evaluated the PK profiles of BDP/FF/GB in Japanese vs Caucasian healthy volunteers and found comparable results between the two ethnicities, with higher exposure of formoterol in Japanese participants. Pharmacodynamic and safety profile results were similar in both ethnicities, with most patients not experiencing any adverse events.
CLINICAL THERAPEUTICS
(2021)